Inflammatory Breast Cancer Clinical Trials 2023

What are the top hospitals conducting inflammatory breast cancer research?

In the realm of clinical trials for inflammatory breast cancer, several leading hospitals are making significant strides in research and treatment. Among them is the renowned M D Anderson Cancer Center in Houston, which currently has 11 active trials focused on this aggressive form of breast cancer. Over time, they have conducted a total of 16 trials since their first recorded study in 2007. This center's dedication to finding innovative solutions puts them at the forefront of advancements in combating this challenging disease.

Meanwhile, located across the country in Boston, two esteemed institutions are also actively contributing to the fight against inflammatory breast cancer. Dana-Farber Cancer Institute is engaged in five ongoing clinical trials addressing this condition and has had an impressive record since initiating their inaugural trial back in 2016 with five studies completed overall. Brigham and Women's Hospital offers three active clinical trials specific to inflammatory breast cancer and shares a similar timeline with their first recorded trial also dating back to 2016.

On the West Coast lies City of Hope Medical Center in Duarte—a hospital that recognizes the urgency surrounding inflammatory breast cancer. With three current active trials dedicated to this particular type of breast cancer, City of Hope Medical Center demonstrates its commitment towards finding effective treatments for patients battling it out against such odds; they started recording these endeavors from as early as2012 when they initiated its very first experimentations on fighting said inflammation-related ailment itself.

Finally,hospital nameoffers support not only through patient care but through research initiatives as well.It may be relatively new compared to some other institutions,butCityofHopeComprehensiveCancerCenterinDuartehas already demonstrated its dedication by conductingtwoactiveclinicaltrialsforinflammatorybreastcancerand havingrecordeditsfirsttrialbackinthe year2017.Trueprogressisachievedthroughthesecollectiveeffortsofleadinghospitalsacrosstheworld,anditisencouragingtoseethesespecificfacilitiespouringtheirtimeandresourcesinto thebattleagainstinflammatorybreastcancer.Throughtheseclinicaltrials,theyarepavingthewaytowardseffective,tailoredtreatmentoptionsforpatientsaffectedbythisrarebutdevastatingformofbreastcancer.

Which are the best cities for inflammatory breast cancer clinical trials?

When it comes to inflammatory breast cancer clinical trials, several cities offer notable opportunities for research and advancement. Houston, Texas, and Boston, Massachusetts both have 13 active trials investigating various treatments like Neratinib, Pembrolizumab, Dasatinib in Houston; Onvansertib, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Eribulin in Boston. Duarte, California follows closely with six ongoing studies exploring treatment options such as Multi-epitope Folate Receptor Alpha Peptide Vaccine and pertuzumab. While Anchorage, Alaska boasts five active trials focusing on Radiation Therapy. Lastly, Miami Florida presents three active trials investigating Treatment and Multi-epitope Folate Receptor Alpha Peptide Vaccine among others. These cities serve as prime locations for individuals seeking participation in clinical trials for inflammatory breast cancer.

Which are the top treatments for inflammatory breast cancer being explored in clinical trials?

Exciting developments in clinical trials bring hope to those battling inflammatory breast cancer. Among the top treatments being explored are:

• Neratinib: Currently undergoing testing in two active trials, with a total of two all-time inflammatory breast cancer trials since its introduction in 2018.
• Pembrolizumab: Showing promise, this treatment is also involved in two ongoing trials and has been part of five all-time studies for inflammatory breast cancer. It was first listed as a potential therapy option in 2015.
• Pharmacological Study: Underway in one active trial and having participated in two all-time inflammatory breast cancer studies since 2003.

Additionally, researchers are investigating the efficacy of Multi-epitope Folate Receptor Alpha Peptide Vaccine through one current trial, representing the sole study dedicated to this approach for treating inflammatory breast cancer thus far (first listed as an option in 2017). These innovative therapies offer renewed optimism to patients facing this aggressive form of cancer.

What are the most recent clinical trials for inflammatory breast cancer?

Recent clinical trials offer new hope for individuals battling inflammatory breast cancer. One such trial focuses on HER2 positive cases, exploring targeted treatments specifically designed for this subtype of the disease. Additionally, onvansertib and neratinib have shown promise in early-phase studies, offering potential options for patients with inflammatory breast cancer. Another notable trial investigates a fixed dose combination of pertuzumab and trastuzumab administered subcutaneously, aiming to enhance treatment efficacy and convenience. Furthermore, dasatinib demonstrates encouraging results as a potential therapeutic option in both phase 1 and phase 2 trials. With these advancements underway, there is renewed optimism for improved outcomes in the fight against inflammatory breast cancer.

What inflammatory breast cancer clinical trials were recently completed?

A recent clinical trial investigating treatments for inflammatory breast cancer has reached a significant milestone, providing valuable insights into potential advancements in this challenging disease. Completed in November 2010 and sponsored by M.D. Anderson Cancer Center, the Nab-paclitaxel trial marked an important step towards improving treatment options for patients with inflammatory breast cancer. While further research is needed to build upon these findings, this study highlights the ongoing efforts of researchers to find innovative solutions against this aggressive form of breast cancer.